Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Hiroyuki Kozai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are a revolutionary paradigm in the treatment of thoracic malignancies and chemoimmunotherapy is a current standard care in this field. Chemotherapeutic agents are known to induce not only direct cytotoxic effects on tumor cells but also immune modulating effects, such as stimulating immunogenic cell death (ICD). Currently, either pemetrexed (PEM) or taxane plus platinum are combined with ICIs for patients with non‐small cell lung cancer (NSCLC); however, it is still unknown whether these agents are immunologically optimal partners for ICIs.
Methods
To determine the immunologically optimal chemotherapeutic agent, we first evaluated the ability of several chemotherapeutic agents, including platinum, PEM, taxane, and 5‐fluorouracil (5‐FU) to induce ICD using several thoracic tumor cell lines in vitro. ICD was evaluated by the cell surface expression of calreticulin (CRT) and adenosine‐triphosphate (ATP) secretion. We further performed an antitumor vaccination assay in vivo.
Results
5‐FU induced cell surface expression of CRT and ATP secretion most efficiently among the several chemotherapeutic agents. This effect was enhanced when it was combined with platinum. In the antitumor vaccination assay in vivo, we found that vaccination with dying‐AB1‐HA (a murine malignant mesothelioma cell line) cells treated with 5‐FU, but neither PEM nor PTX, reduced the tumor growth of living‐AB1‐HA cells inoculated 1 week after vaccination by recruiting CD3 + CD8 + T cells into the tumor microenvironment.
Conclusion
Our findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Community Medicine for Respirology, Hematology, and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
ORCID-Profile: Hiroshi Nokihara, Yasuhiko Nishioka
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kozai, H., Ogino, H., Mitsuhashi, A., Nguyen, N. T., Tsukazaki, Y., Yabuki, Y., Ozaki, R., Yoneda, H., Sato, S., Hanibuchi, M., Shinohara, T., Nokihara, H., & Nishioka, Y. (2024). Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15200
Vancouver
Kozai H, Ogino H, Mitsuhashi A, Nguyen NT, Tsukazaki Y, Yabuki Y, et al. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15200
BibTeX
@article{Kozai2024,
author = {Kozai, Hiroyuki and Ogino, Hirokazu and Mitsuhashi, Atsushi and Nguyen, Na Thi and Tsukazaki, Yuki and Yabuki, Yohei and Ozaki, Ryohiko and Yoneda, Hiroto and Sato, Seidai and Hanibuchi, Masaki and Shinohara, Tsutomu and Nokihara, Hiroshi and Nishioka, Yasuhiko},
title = {Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15200}
}
EUVIMED